- Home
- KGEI vs MNPR Comparison
KGEI vs MNPR Comparison
Compare KGEI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- MNPR
- Stock Information
- Founded
- KGEI 2008
- MNPR 2014
- Country
- KGEI United States
- MNPR United States
- Employees
- KGEI N/A
- MNPR N/A
- Industry
- KGEI
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- KGEI
- MNPR Health Care
- Exchange
- KGEI Nasdaq
- MNPR Nasdaq
- Market Cap
- KGEI 262.6M
- MNPR 244.1M
- IPO Year
- KGEI N/A
- MNPR 2019
- Fundamental
- Price
- KGEI $8.91
- MNPR $33.43
- Analyst Decision
- KGEI Strong Buy
- MNPR Strong Buy
- Analyst Count
- KGEI 1
- MNPR 5
- Target Price
- KGEI $11.00
- MNPR $49.60
- AVG Volume (30 Days)
- KGEI 126.3K
- MNPR 30.2K
- Earning Date
- KGEI 03-25-2025
- MNPR 05-08-2025
- Dividend Yield
- KGEI N/A
- MNPR N/A
- EPS Growth
- KGEI N/A
- MNPR N/A
- EPS
- KGEI 0.50
- MNPR N/A
- Revenue
- KGEI $58,651,000.00
- MNPR N/A
- Revenue This Year
- KGEI $39.41
- MNPR N/A
- Revenue Next Year
- KGEI $24.46
- MNPR N/A
- P/E Ratio
- KGEI $17.70
- MNPR N/A
- Revenue Growth
- KGEI 15.91
- MNPR N/A
- 52 Week Low
- KGEI $2.85
- MNPR $1.72
- 52 Week High
- KGEI $9.89
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- KGEI 56.36
- MNPR 45.29
- Support Level
- KGEI $6.57
- MNPR $36.80
- Resistance Level
- KGEI $8.71
- MNPR $43.00
- Average True Range (ATR)
- KGEI 0.57
- MNPR 5.63
- MACD
- KGEI 0.08
- MNPR 0.16
- Stochastic Oscillator
- KGEI 78.97
- MNPR 21.49
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. Its segments include the United States, Canada and Others. The company derives a majority of its revenue from the United States.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.